Bevacizumab
A monoclonal antibody that blocks a protein called VEGF, which tumors use to stimulate the growth of new blood vessels needed for their survival. By cutting off this blood supply, it is used to treat various cancers including colorectal, lung, and ovarian cancer, as well as certain eye conditions involving abnormal vessel growth. It is given intravenously and can cause side effects including high blood pressure and impaired wound healing.
治療領域
作用機序
Binds to a specific target antigen on tumor cells or immune cells, triggering immune-mediated destruction through antibody-dependent cellular cytotoxicity (ADCC), complement-dependent cytotoxicity (CDC), or direct signaling inhibition.
Pharmacokinetics (PK)
Pharmacodynamics (PD)
Binds to a specific target antigen on tumor cells or immune cells, triggering immune-mediated destruction through antibody-dependent cellular cytotoxicity (ADCC), complement-dependent cytotoxicity (CDC), or direct signaling inhibition.
HBD / HBA
- / -
No targets recorded
Target interaction data is not yet available for this drug.
No interactions recorded
Drug interaction data is not yet available for this compound.
No side effects recorded
Side effect data is not yet available for this drug.
よくある質問
A monoclonal antibody that blocks a protein called VEGF, which tumors use to stimulate the growth of new blood vessels needed for their survival. By cutting off this blood supply, it is used to treat various cancers including colorectal, lung, and ovarian cancer, as well as certain eye conditions involving abnormal vessel growth. It is given intravenously and can cause side effects including high blood pressure and impaired wound healing.
Binds to a specific target antigen on tumor cells or immune cells, triggering immune-mediated destruction through antibody-dependent cellular cytotoxicity (ADCC), complement-dependent cytotoxicity (CDC), or direct signaling inhibition.
Yes, Bevacizumab is an approved drug. It has reached clinical phase 4. It is classified as a Antibody.
References & Data Sources
- ChEMBL — European Bioinformatics Institute (EBI). CHEMBL1201583. Open-access bioactivity database.
Data aggregated from publicly available pharmacological databases. Last updated 2026-02-27.
Embed This Widget
Add the script tag and a data attribute to embed this widget.
<script src="https://cdn.jsdelivr.net/npm/drugfyi-embed@1/dist/embed.min.js" defer></script>
<div data-drugfyi="drug" data-slug="bevacizumab"></div>Embed via iframe for maximum compatibility.
<iframe src="https://drugfyi.com/iframe/drug/bevacizumab/" width="420" height="400" frameborder="0" style="border:0;border-radius:10px;max-width:100%" loading="lazy"></iframe>Paste this URL in WordPress, Medium, or any oEmbed-compatible platform.
https://drugfyi.com/drug/bevacizumab/Add a dynamic SVG badge to your README or docs.
[](https://drugfyi.com/drug/bevacizumab/)Use the native HTML custom element.
<script src="https://cdn.jsdelivr.net/npm/drugfyi-embed@1/dist/embed.min.js" defer></script>
<drugfyi-drug slug="bevacizumab"></drugfyi-drug>